GRDX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About GRDX Interactive Breakdown Better Bets vs. GRDX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    GridAI Technologies (GRDX)

    Market Price (11/6/2026): $4.72 | Market Cap: $42.0 MilSector: Health Care | Industry: Biotechnology

    GridAI Technologies (GRDX)

    Market Price (11/6/2026): $4.72
    Market Cap: $42.0 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Megatrend and thematic drivers
    Megatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more.

    Weak multi-year price returns
    3Y Excs Rtn is -156%

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7655%

    Expensive valuation multiples
    P/SPrice/Sales ratio is 187x

    Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1284%

    Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5065%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5065%

    Valuation getting more expensive
    P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55%

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -73%

    High stock price volatility
    Vol 12M is 129%

    Key risks
    GRDX key risks include [1] internal governance friction following recent director resignations, Show more.

    0 Megatrend and thematic drivers
    Megatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more.
    1 Weak multi-year price returns
    3Y Excs Rtn is -156%
    2 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7655%
    3 Expensive valuation multiples
    P/SPrice/Sales ratio is 187x
    4 Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1284%
    5 Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5065%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5065%
    6 Valuation getting more expensive
    P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55%
    7 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -73%
    8 High stock price volatility
    Vol 12M is 129%
    9 Key risks
    GRDX key risks include [1] internal governance friction following recent director resignations, Show more.

    Valuation & Metrics

    FYE: 12/31GRDX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.2 Mil—
    FY 2026 Sales$22.3 Mil—
    FY 2027 Sales$27.5 Mil—
    FY 2026 Sales Growth13,786.6%—
    FY 2027 Sales Growth23.5%8.7%
    EARNINGS
    LTM Net Income (GAAP) [3]$-20.5 Mil—
    FY 2026 Net Income (Non-GAAP)$-8.4 Mil—
    FY 2027 Net Income (Non-GAAP)$-8.0 Mil—
    FY 2027 Net Income Growth—13.9%
    FY 2026 EPS (Non-GAAP)$-5.22—
    FY 2027 EPS (Non-GAAP)$-4.95—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S1.91.7
    FY 2027 P/S1.5—
    FY 2026 P/E—8.7
    FY 2027 P/E——

    [1] GRDX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 11/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    GRDXS&P 500
    REVENUE GROWTHFAIR
    Rev LTM ($ Bil)0.0
    Rev Chg Q�8.9%
    Rev Chg LTM�8.6%
    PROFITABILITYVERY POOR
    Op Inc LTM ($ Bil)-0.0
    CFO LTM ($ Bil)-0.0
    Net Inc LTM ($ Bil)-0.0
    Op Mgn LTM-7,655.4%18.9%
    CFO/Rev LTM-5,064.9%21.5%
    Net Inc Mgn-12,789.6%13.5%
    VALUATIONVERY HIGH
    P/S189.03.2
    P/CFO-3.715.1
    P/FCF-3.720.2
    P/E-1.522.3
    STABILITYGOOD
    Debt/Equity0.060.19
    Cash/Assets0.040.07

    AI Analysis | Feedback

    MetricValueDateSource
    Projected annual revenue from the initial deployment with a hyperscaler data center developer (2027 projection)Approximately $8 million11192025Link
    Projected annual revenue from the initial deployment with a hyperscaler data center developer (2029 projection)Over $50 million11192025Link

    Price Chart

    null
    Upcoming
    11/16/2026Earnings ReleaseRev: $85876 (E)
    EPS: $-11,340.00 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 11/5/2026

    GridAI Technologies (GRDX) stock has gained about 60% since 7/31/2026 because of the following key factors:

    1. Strategic Focus on AI-Powered Energy Orchestration and Major Partnership. GridAI Technologies Corp. significantly advanced its strategic pivot towards AI-powered energy orchestration, a core component of its business following the acquisition of Grid AI Corp. in late fiscal year 2025. A major catalyst for investor confidence was the identification of Amp Z in March 2026 as a hyperscaler AI data center developer. GridAI is set to provide energy orchestration for Amp Z's planned portfolio of over 5GW of AI data center campuses over the next 5-10 years, a partnership expected to generate recurring software fees and performance-based revenue.

    2. Strong Sequential Growth in Fiscal Q2 2026 Earnings. The company reported its fiscal Q2 2026 earnings, for the quarter ending June 30, 2026, which revealed a net loss of -$12.9 million. However, this represented a substantial sequential improvement, with earnings showing a 255% growth compared to the prior fiscal quarter. This significant operational improvement, reported around the start of the specified period, likely signaled positive momentum to investors, contributing to the stock's upward trend.

    Show more
    Updated on 11/5/2026

    GridAI Technologies (GRDX) stock has gained about 60% since 7/31/2026 because of the following key factors:

    1. Strategic Focus on AI-Powered Energy Orchestration and Major Partnership. GridAI Technologies Corp. significantly advanced its strategic pivot towards AI-powered energy orchestration, a core component of its business following the acquisition of Grid AI Corp. in late fiscal year 2025. A major catalyst for investor confidence was the identification of Amp Z in March 2026 as a hyperscaler AI data center developer. GridAI is set to provide energy orchestration for Amp Z's planned portfolio of over 5GW of AI data center campuses over the next 5-10 years, a partnership expected to generate recurring software fees and performance-based revenue.

    2. Strong Sequential Growth in Fiscal Q2 2026 Earnings. The company reported its fiscal Q2 2026 earnings, for the quarter ending June 30, 2026, which revealed a net loss of -$12.9 million. However, this represented a substantial sequential improvement, with earnings showing a 255% growth compared to the prior fiscal quarter. This significant operational improvement, reported around the start of the specified period, likely signaled positive momentum to investors, contributing to the stock's upward trend.

    3. Access to Capital and Strengthening Financial Position. In October 2026, GridAI Technologies secured additional funding through expanded convertible note financing with Pronghorn Resources and completed warrant-based private financing rounds. These financing activities demonstrated continued investor interest and provided the company with capital to support its ongoing operations and growth initiatives, reinforcing its financial position during a period of strategic expansion into the AI data center market.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The 61.0% change in GRDX stock from 7/31/2026 to 11/5/2026 was primarily driven by a 115.3% change in the company's Total Revenues ($ Mil).
    (LTM values as of)731202611052026Change
    Stock Price ($)2.904.6761.0%
    Change Contribution By: 
    Total Revenues ($ Mil)00115.3%
    P/S Multiple173.4187.07.8%
    Shares Outstanding (Mil)46-30.7%
    Cumulative Contribution61.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2026 to 11/5/2026
    ReturnCorrelation
    GRDX61.0% 
    Market (SPY)-1.9%28.5%
    Sector (XLV)13.8%11.1%

    Fundamental Drivers

    The 86.1% change in GRDX stock from 4/30/2026 to 11/5/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).
    (LTM values as of)430202611052026Change
    Stock Price ($)2.514.6786.1%
    Change Contribution By: 
    Total Revenues ($ Mil)009.2233720368547763E17%
    P/S Multiple∞187.0 
    Shares Outstanding (Mil)26-74.3%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    4/30/2026 to 11/5/2026
    ReturnCorrelation
    GRDX86.1% 
    Market (SPY)2.3%27.9%
    Sector (XLV)27.2%0.7%

    Fundamental Drivers

    The 9.9% change in GRDX stock from 10/31/2025 to 11/5/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).
    (LTM values as of)1031202511052026Change
    Stock Price ($)4.254.679.9%
    Change Contribution By: 
    Total Revenues ($ Mil)009.2233720368547763E17%
    P/S Multiple∞187.0 
    Shares Outstanding (Mil)56-25.8%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    10/31/2025 to 11/5/2026
    ReturnCorrelation
    GRDX9.9% 
    Market (SPY)8.4%26.0%
    Sector (XLV)29.8%8.5%

    Fundamental Drivers

    The -73.0% change in GRDX stock from 10/31/2023 to 11/5/2026 was primarily driven by a null change in the company's P/S Multiple.
    (LTM values as of)1031202311052026Change
    Stock Price ($)17.324.67-73.0%
    Change Contribution By: 
    Total Revenues ($ Mil)009.2233720368547763E17%
    P/S Multiple∞187.0 
    Shares Outstanding (Mil)06-99.4%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    10/31/2023 to 11/5/2026
    ReturnCorrelation
    GRDX-73.0% 
    Market (SPY)81.3%6.0%
    Sector (XLV)55.5%2.4%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    GRDX Return-85%-98%-97%-85%150%0%-100%
    Peers Return52%-31%92%61%33%-1%326%
    S&P 500 Return27%-19%24%23%16%12%105%

    Monthly Win Rates [3]
    GRDX Win Rate17%8%8%42%42%36% 
    Peers Win Rate65%33%72%70%55%49% 
    S&P 500 Win Rate75%42%67%75%67%45% 

    Max Drawdowns [4]
    GRDX Max Drawdown-94%-99%-98%-97%-64%-62% 
    Peers Max Drawdown-15%-42%-17%-20%-28%-28% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: MSFT, GOOGL, AMZN, NVDA, IBM.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 11/5/2026 (YTD)

    How Low Can It Go

    EventGRDXS&P 500
    2025 US Tariff Shock
      % Loss-33.2%-18.8%
      % Gain to Breakeven49.8%23.1%
      Time to Breakeven37 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-78.6%-7.8%
      % Gain to Breakeven367.0%8.5%
      Time to Breakeven403 days18 days
    2020 COVID-19 Crash
      % Loss-48.4%-33.7%
      % Gain to Breakeven93.8%50.9%
      Time to Breakeven85 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-61.4%-19.2%
      % Gain to Breakeven159.0%23.8%
      Time to Breakeven135 days105 days

    Compare to MSFT, GOOGL, AMZN, NVDA, IBM

    In The Past

    GridAI Technologies's stock fell -33.2% during the 2025 US Tariff Shock. Such a loss loss requires a 49.8% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventGRDXS&P 500
    2025 US Tariff Shock
      % Loss-33.2%-18.8%
      % Gain to Breakeven49.8%23.1%
      Time to Breakeven37 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-78.6%-7.8%
      % Gain to Breakeven367.0%8.5%
      Time to Breakeven403 days18 days
    2020 COVID-19 Crash
      % Loss-48.4%-33.7%
      % Gain to Breakeven93.8%50.9%
      Time to Breakeven85 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-61.4%-19.2%
      % Gain to Breakeven159.0%23.8%
      Time to Breakeven135 days105 days

    Compare to MSFT, GOOGL, AMZN, NVDA, IBM

    In The Past

    GridAI Technologies's stock fell -33.2% during the 2025 US Tariff Shock. Such a loss loss requires a 49.8% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About GridAI Technologies (GRDX)

    Entero Therapeutics, Inc. (GRDX) is a clinical-stage biopharmaceutical company dedicated to developing innovative, targeted, and orally delivered therapies for a variety of gastrointestinal diseases. The company focuses on addressing significant unmet medical needs within this therapeutic area by advancing its pipeline of novel drug candidates.

    The company's robust product pipeline features several key candidates undergoing clinical trials. Latiglutenase, a targeted oral biotherapeutic, is in Phase 2 studies for celiac disease, specifically designed to break down gluten into non-immunogenic peptides. Another candidate, capeserod, a selective 5-HT4 receptor partial agonist, is under Phase 1 studies for the treatment of gastroparesis. Entero Therapeutics is also developing adrulipase, a recombinant lipase enzyme in Phase 2 studies, aimed at improving the digestion of fats and other nutrients for patients with exocrine pancreatic insufficiency caused by cystic fibrosis or chronic pancreatitis. Furthermore, niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, is in Phase 2 studies for conditions such as ulcerative proctitis, ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

    In summary, Entero Therapeutics, Inc. targets specialized patient populations suffering from various complex gastrointestinal conditions. Through its diversified pipeline, the company aims to provide new and effective treatment options by advancing its therapies through different stages of clinical development.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    The key risks for GridAI Technologies (GRDX) are primarily associated with the inherent challenges of its diversified business model, encompassing both late clinical-stage biopharmaceutical development and a new venture into AI-driven energy orchestration software.

    1. Clinical Development and Regulatory Approval Risk: As a late clinical-stage biopharmaceutical company, GridAI Technologies faces substantial risks associated with the development of its pipeline candidates, including latiglutenase, capeserod, adrulipase, and niclosamide. The high failure rate of clinical trials means that these candidates may not prove to be safe or effective, or may experience significant delays or unexpected adverse events. Failure to successfully complete clinical trials or obtain necessary regulatory approvals from health authorities would prevent the company from bringing its therapies to market, significantly impacting its financial viability and future prospects.
    2. Market Adoption and Competitive Risk in AI/Energy Sector: GridAI Technologies' recent diversification into AI-native energy-orchestration software introduces risks related to market acceptance and intense competition. The company's platform aims to coordinate grid power and manage energy systems for hyperscale AI campuses and distributed energy, a rapidly evolving and competitive market. There is a risk that the company's technology may not achieve sufficient market adoption, or that existing or new competitors could offer superior or more cost-effective solutions, limiting GridAI Technologies' ability to generate substantial revenue from this new segment.
    3. Funding and Commercialization Risk: Both the biopharmaceutical development and the scaling of a new AI/energy software platform are capital-intensive endeavors. GridAI Technologies currently operates with a relatively small market capitalization and negative EBITDA, indicating a reliance on external financing to fund ongoing operations, clinical trials, and technological development. The inability to secure adequate funding in the future, or challenges in successfully commercializing its products and software even if approved or adopted, could severely constrain the company's growth and operational continuity.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Here are 3-5 expected drivers of future revenue growth for GridAI Technologies (GRDX) over the next 2-3 years:

    1. Addressing Hyperscale AI Data Center Energy Demand: GridAI Technologies is positioned to capitalize on the rapidly increasing electricity consumption and complex energy management needs of hyperscale AI data centers. The company develops grid and power-management software aimed at these campuses, providing an AI-driven energy orchestration platform that optimizes energy usage, manages grid connections, and coordinates distributed energy resources. With AI data centers projected to drive significant incremental power demand in the coming years, the demand for GridAI's solutions in this sector is a key revenue driver.
    2. Expansion and Adoption of the AI-Driven Energy Orchestration Platform: The company's core technology, an AI-driven software and control platform, enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems, on-site generation, and renewables. As the energy landscape becomes more complex due to electrification and distributed energy resources, the increased adoption of this platform by a broader range of customers, seeking to improve efficiency, reduce costs, and participate in grid services markets, is expected to drive revenue growth.
    3. Continued Advancement of Biopharmaceutical Pipeline: Despite its expanded focus on AI and energy infrastructure, GridAI Technologies (formerly Entero Therapeutics, Inc.) continues to advance its late clinical-stage biopharmaceutical programs targeting gastrointestinal diseases. The company's pipeline includes candidates such as latiglutenase for celiac disease (Phase 2), capeserod for gastroparesis (Phase 1), adrulipase for exocrine pancreatic insufficiency (Phase 2), and niclosamide for ulcerative proctitis/proctosigmoiditis and immune checkpoint inhibitor-associated colitis/diarrhea (Phase 2). Successful progression through clinical trials and potential commercialization of these therapeutic candidates represent significant future revenue opportunities.

    AI Analysis | Feedback

    null

    Peer Outperformance in Biotechnology

    GRDX has trailed 96% of its 363 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that GRDX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    69%
    of 452 industry peers · 10.7% return
    3Y
    32%
    of 398 industry peers · -73.2% return
    5Y
    4%
    of 363 industry peers · -100.0% return
    No Biotechnology peer with a comparable growth profile has beaten GRDX by more than 20pp over 5Y.
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is GRDX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 7.6%56.6%93.6% CAH 498% · MCK 396% · COR 181%
    Health Care Services 20 33.8%28.8%6.1% HIMS 189% · RDNT 125% · DGX 100%
    Health Care Facilities 25 13.9%27.4%-1.4% THC 280% · NHC 210% · EHC 186%
    Managed Health Care 8 47.9%1.6%-2.2% OSCR 95% · HQY 52% · ELV 10%
    Health Care Equipment 50 11.0%17.8%-17.6% UFPT 355% · GKOS 286% · PLSE 127%
    Pharmaceuticals 61 -12.9%10.6%-37.3% LQDA 977% · XERS 571% · KNSA 500%
    Health Care Supplies 11 23.9%17.0%-40.1% LNTH 248% · HAE 66% · MMSI 29%
    Life Sciences Tools & Services 108 -8.1%-18.9%-74.5% AXGN 255% · NTRA 214% · MEDP 181%
    Biotechnology ← 364 -25.8%-36.1%-82.0% ELVN 1073% · TRVI 995% · DNTH 956%
    Health Care Technology 21 -21.4%-50.4%-82.8% VEEV -3% · DOCS -51%
    Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ULHUniversal Logistics0.869.2%97.6%
    CRCTCricut1.949.7%95.1%
    ARRYArray Technologies0.848.9%-42.5%
    DNUTKrispy Kreme0.843.7%14.4%
    GDYNGrid Dynamics1.142.6%49.9%
    APPAppLovin119.639.7%-47.2%
    EVEREverQuote1.133.0%12.3%
    AGLAgilon Health1.932.4%560.8%
    CPRICapri2.331.6%-13.4%
    GPKGraphic Packaging3.431.0%-20.8%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    VCYTVeracyte1.9-54.0%-43.0%
    MNTNMNTN0.3-52.2%-60.6%
    FRMIFermi1.0-46.5%-80.9%
    NRIXNurix Therapeutics1.7-45.3%-21.8%
    LITELumentum43.5-44.6%38.3%
    ACDCProFrac0.5-44.1%-30.3%
    PCTPureCycle Technologies0.3-43.5%-78.1%
    INTCIntel274.0-43.2%41.6%
    OFRMOnce Upon a Farm PBC0.4-42.7%-56.5%
    AESIAtlas Energy Solutions0.7-42.5%-43.5%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    BMBLBumble0.8139.2%67.5%
    GDYNGrid Dynamics1.176.5%49.9%
    ULHUniversal Logistics0.872.3%97.6%
    TDOCTeladoc Health1.769.2%34.4%
    SGRYSurgery Partners3.069.0%50.0%
    LQDALiquidia4.066.8%29.0%
    ENOVEnovis1.662.5%7.4%
    BRZEBraze5.161.0%33.6%
    UPBDUpbound1.559.3%51.6%
    COAGHemab Therapeutics1.458.8%34.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CIFRCipher Digital2.3-61.9%-62.4%
    AAOIApplied Optoelectronics3.8-61.7%34.5%
    FRMIFermi1.0-61.5%-80.9%
    MXLMaxLinear4.0-58.7%154.2%
    AESIAtlas Energy Solutions0.7-57.3%-43.5%
    FPSForgent Power Solutions4.7-55.2%-37.2%
    STRLSterling Infrastructure7.5-54.3%-20.2%
    LITELumentum43.5-54.1%38.3%
    AXTIAXT2.2-54.0%124.6%
    ICHRIchor1.0-54.0%52.1%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    GRDXMSFTGOOGLAMZNNVDAIBMMedian
    NameGridAI T.MicrosoftAlphabet Amazon.c.NVIDIA Internat. 
    Mkt Price4.72530.70282.45260.70189.24244.00252.35
    Mkt Cap0.03,941.03,461.72,814.84,577.7230.43,138.2
    Rev LTM0346,445471,098797,455302,96969,870324,707
    Op Inc LTM-12163,191156,976104,366197,57912,808130,671
    FCF LTM-859,95719,747-46,892127,00614,01816,882
    FCF 3Y Avg-870,21249,7072,20781,93812,58731,147
    CFO LTM-8195,878179,551168,300134,36015,831151,330
    CFO 3Y Avg-8155,021145,359137,23286,68614,297111,959

    Growth & Margins

    GRDXMSFTGOOGLAMZNNVDAIBMMedian
    NameGridAI T.MicrosoftAlphabet Amazon.c.NVIDIA Internat. 
    Rev Chg LTM-17.9%22.2%15.4%83.4%6.8%17.9%
    Rev Chg 3Y Avg-16.6%16.7%12.9%116.5%4.5%16.6%
    Rev Chg Q-18.8%24.7%12.1%105.9%4.7%18.8%
    QoQ Delta Rev Chg LTM115.3%4.4%5.7%2.8%19.5%1.1%5.0%
    Op Inc Chg LTM-169.4%20.0%26.5%37.0%105.9%10.9%23.3%
    Op Inc Chg 3Y Avg-106.3%20.2%26.0%64.1%206.3%11.5%23.1%
    Op Mgn LTM-7,655.4%47.1%33.3%13.1%65.2%18.3%25.8%
    Op Mgn 3Y Avg-46.0%32.1%11.3%61.7%17.2%32.1%
    QoQ Delta Op Mgn LTM5,609.0%0.3%0.2%1.0%1.2%-0.1%0.7%
    CFO/Rev LTM-5,064.9%56.5%38.1%21.1%44.3%22.7%30.4%
    CFO/Rev 3Y Avg-51.5%36.1%19.4%47.2%21.7%36.1%
    FCF/Rev LTM-5,064.9%17.3%4.2%-5.9%41.9%20.1%10.7%
    FCF/Rev 3Y Avg-24.1%13.2%0.9%44.7%19.1%19.1%

    Valuation

    GRDXMSFTGOOGLAMZNNVDAIBMMedian
    NameGridAI T.MicrosoftAlphabet Amazon.c.NVIDIA Internat. 
    Mkt Cap0.03,941.03,461.72,814.84,577.7230.43,138.2
    P/S189.011.47.33.515.13.39.4
    P/Op Inc-2.524.122.127.023.218.022.6
    P/EBIT-1.421.811.915.819.918.517.1
    P/E-1.527.614.720.923.720.620.8
    P/CFO-3.720.119.316.734.114.618.0
    Total Yield-68.4%4.3%7.1%4.8%4.5%7.5%4.7%
    Dividend Yield0.0%0.7%0.3%0.0%0.2%2.7%0.2%
    FCF Yield 3Y Avg-190.8%2.0%1.9%0.3%2.0%5.7%1.9%
    D/E0.10.00.00.10.00.30.1
    Net D/E0.0-0.0-0.00.1-0.00.20.0

    Returns

    GRDXMSFTGOOGLAMZNNVDAIBMMedian
    NameGridAI T.MicrosoftAlphabet Amazon.c.NVIDIA Internat. 
    1M Rtn13.2%0.3%-18.8%1.7%-20.9%10.3%1.0%
    3M Rtn63.9%6.4%-21.0%-4.2%-13.5%5.3%0.5%
    6M Rtn65.6%26.6%-28.9%-3.9%-10.3%7.0%1.6%
    12M Rtn11.8%5.5%-0.4%4.2%-2.8%-18.4%1.9%
    3Y Rtn-72.9%52.3%118.9%86.6%314.9%79.7%83.1%
    1M Excs Rtn16.0%1.6%-18.0%1.8%-18.8%12.1%1.7%
    3M Excs Rtn73.2%7.2%-19.3%-4.1%-14.5%4.4%0.2%
    6M Excs Rtn60.8%21.9%-33.7%-8.7%-15.3%2.3%-3.2%
    12M Excs Rtn2.6%-9.4%-11.5%-9.0%-18.6%-30.2%-10.4%
    3Y Excs Rtn-157.0%-21.9%46.5%12.4%278.6%2.8%7.6%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/21/20265/27/20265/1/202611/19/20258/14/20255/15/20254/1/202511/13/202410/21/20245/14/20243/29/202411/13/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-12-3-4-1-1-1-1-2-3-9-4-3
    Operating Income-3-4-5-1-1-1-1-2-3-9-4-3
    Net Income-13-4-3-1-1-1-12-3-96-4-3
    EPS-2.01-0.82-1.88-0.75-0.23-0.84-10.03-1.76-11.589.36-8.03-27.63
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-20-8-7-4-5-7-16-18-20-21-16-16
    Operating Income TTM-12-10-7-4-5-7-16-19-20-21-16-14
    Net Income TTM-21-9-6-16-17-25-18-10-11-6-16-16
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-1799.2%-183.8%-241.8%50.6%81.2%89.8%70.5%44.8%18.8%-124.1%-2.9%-177.9%
    Operating Income Growth-375.3%-340.0%-289.6%50.6%81.4%91.0%70.6%44.9%18.1%-124.0%-79.6%-178.2%
    Net Income Growth-1184.1%-182.0%75.6%55.3%88.7%-122.6%-198.4%24.8%-110.2%236.8%-2.9%-178.2%
    Margins Quarterly            
    EBITDA Margin-14129.2%-6908.3%-11347.8%---------
    Operating Income Margin-3536.1%-9460.1%-12933.2%---------
    Net Income Margin-14927.4%-9297.7%-8225.9%---------
    Cash & Debt            
    Total Cash101300001343
    Total Debt232111000710
    Net Debt / (Cash)121-111-0-0-04-3-3
    Cash Flows Quarterly            
    FCF from Operations-2-2-4-1-0-1-0-2-3-4-3-3
    Cash Flows TTM            
    FCF from Operations TTM-8-7-6-2-3-6-9-12-14-13-12-15
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-5.1%-5.6%-7.2%-1.3%-1.0%-1.3%-1.9%-2.9%-5.3%-14.0%-8.8%-7.6%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-4.9%-3.9%-2.8%-1.2%-1.7%-2.8%-6.0%-7.1%-7.8%-8.0%-8.5%-7.7%

    Segment Financials

    Revenue by Segment
    $ Mil20252024
    Grid AI Corp (artificial intelligence (AI Segment))00
    GridAI Technologies Corp (gastrointestinal therapies (GI Segment))00
    Total00


    Operating Income by Segment
    $ Mil202520242023
    Grid AI Corp (artificial intelligence (AI Segment))-30 
    GridAI Technologies Corp (gastrointestinal therapies (GI Segment))-4-16 
    Research and development  -5
    Total-7-16-5


    Net Income by Segment
    $ Mil20252024
    Grid AI Corp (artificial intelligence (AI Segment))-10
    GridAI Technologies Corp (gastrointestinal therapies (GI Segment))-5-18
    Total-7-18


    Assets by Segment
    $ Mil20232022202120202019
    Single segment7512139
    Total7512139


    Price Behavior

    Price Behavior
    Market Price$4.67 
    Market Cap ($ Bil)0.0 
    First Trading Date10/11/2016 
    Distance from 52W High-31.3% 
       50 Days200 Days
    DMA Price$4.09$3.54
    DMA Trendupup
    Distance from DMA14.2%31.8%
     3M1YR
    Volatility111.0%128.5%
    Downside Capture-79.49254.65
    Upside Capture343.82253.03
    Correlation (S&P 500)22.4%24.2%
    GRDX Betas & Captures as of 10/31/2026

     1M2M3M6M1Y3Y
    Beta3.201.340.941.912.260.47
    Up Beta11.271.57-1.160.410.68-0.23
    Down Beta1.924.335.322.433.300.75
    Up Capture770%153%170%419%450%14%
    Bmk +ve Days12182862130427
    Stock +ve Days12213162115338
    Down Capture125%-102%-185%122%163%103%
    Bmk -ve Days10253664121325
    Stock -ve Days10223364133402

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GRDX
    GRDX15.1%128.5%0.70-
    Sector ETF (XLV)29.2%16.9%1.338.5%
    Equity (SPY)9.5%13.6%0.4126.2%
    Gold (GLD)3.6%28.7%0.115.0%
    Commodities (DBC)37.7%21.2%1.40-12.6%
    Real Estate (VNQ)12.0%14.2%0.558.6%
    Bitcoin (BTCUSD)-20.8%43.3%-0.4211.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GRDX
    GRDX-82.9%141.0%-0.59-
    Sector ETF (XLV)8.6%15.4%0.363.6%
    Equity (SPY)11.3%17.3%0.488.9%
    Gold (GLD)17.5%19.1%0.74-1.7%
    Commodities (DBC)8.0%19.6%0.29-1.5%
    Real Estate (VNQ)1.2%18.9%-0.054.4%
    Bitcoin (BTCUSD)5.9%51.5%0.292.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GRDX
    GRDX-69.3%118.5%-0.44-
    Sector ETF (XLV)12.2%16.8%0.606.7%
    Equity (SPY)14.9%18.0%0.7010.6%
    Gold (GLD)12.0%16.5%0.59-0.8%
    Commodities (DBC)7.6%18.1%0.332.0%
    Real Estate (VNQ)5.7%20.7%0.236.2%
    Bitcoin (BTCUSD)61.3%66.2%1.013.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date10152026
    Short Interest: Shares Quantity0.1 Mil
    Short Interest: % Change Since 9302026-5.1%
    Average Daily Volume0.1 Mil
    Days-to-Cover Short Interest1
    Basic Shares Quantity6.4 Mil
    Short % of Basic Shares1.5%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/21/202610-Q
    03/31/202605/27/202610-Q
    12/31/202505/01/202610-K
    09/30/202511/19/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/15/202510-Q
    12/31/202404/01/202510-K
    09/30/202411/13/202410-Q
    06/30/202410/21/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/29/202410-K
    09/30/202311/13/202310-Q
    06/30/202308/14/202310-Q
    03/31/202305/12/202310-Q
    12/31/202203/20/202310-K
    09/30/202211/14/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/21/202610-Q
    03/31/202605/27/202610-Q
    12/31/202505/01/202610-K
    09/30/202511/19/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/15/202510-Q
    12/31/202404/01/202510-K
    09/30/202411/13/202410-Q
    06/30/202410/21/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/29/202410-K
    09/30/202311/13/202310-Q
    06/30/202308/14/202310-Q
    03/31/202305/12/202310-Q
    12/31/202203/20/202310-K
    09/30/202211/14/202210-Q
    06/30/202208/15/202210-Q
    03/31/202205/23/202210-Q
    12/31/202103/31/202210-K
    09/30/202111/15/202110-Q
    06/30/202108/16/202110-Q
    03/31/202105/24/202110-Q
    12/31/202003/31/202110-K
    09/30/202011/16/202010-Q
    06/30/202008/14/202010-Q
    03/31/202005/15/202010-Q
    12/31/201903/30/202010-K
    09/30/201911/14/201910-Q

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 11/5/2026